Allopurinol pharmacogenetics: assessment of potential clinical usefulness (Q34236067)

31 July 2017

Allopurinol pharmacogenetics: assessment of potential clinical usefulness (English)

1 reference

31 July 2017

1 reference

Issam Zineh

1

1 reference

31 July 2017

Padmaja Mummaneni

2

1 reference

31 July 2017

Jenna Lyndly

3

1 reference

31 July 2017

Shashi Amur

4

1 reference

31 July 2017

Lois A La Grenade

5

1 reference

31 July 2017

Stephen H Chang

6

1 reference

31 July 2017

Hobart Rogers

7

1 reference

31 July 2017

Michael A Pacanowski

8

1 reference

31 July 2017

1 December 2011

1 reference

31 July 2017

1 reference

31 July 2017

12

1 reference

31 July 2017

12

1 reference

31 July 2017

1741-1749

1 reference

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

31 July 2017

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.131

Update on emerging urate-lowering therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.131

Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.131

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.131

Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.131

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.131

HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.131

Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.131

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.131

Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.131

Pharmacogenetics and human genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.131

A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.131

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.131

21 January 2018

Identifiers

DOI

10.2217/PGS.11.131

1 reference

31 July 2017

1 reference